| [1] |
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 Study[J]. Circulation, 2014, 129(8):837-847.
|
| [2] |
Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association[J]. Circulation, 2019, 139(10):e56-e528.
|
| [3] |
Michniewicz E, Mlodawska E, Lopatowska P, et al. Patients with atrial fibrillation and coronary artery disease-double trouble[J]. Adv Med Sci, 2018, 63(1): 30-35.
|
| [4] |
杨艳敏, 张晗, 朱俊, 等. 中国急诊心房颤动注册研究:基线资料及治疗情况分析[J]. 中华心律失常学杂志, 2019, 23(1): 12-17.
|
| [5] |
Bai Y, Zhu J, Yang YM, et al. Clinical characteristics and one year outcomes in Chinese atrial fibrillation patients with stable coronary artery disease: a population-based study[J]. J Geriatr Cardiol, 2016, 13(8):665-671.
|
| [6] |
Rohla M, Vennekate CK, Tentzeris I, et al. Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease[J]. Int J Cardiol, 2015, 184:108-114.
|
| [7] |
Dai Y, Yang J, Gao Z, et al. Atrial fibrillation in patients hospitalized with acute myocardial infarction: analysis of the china acute myocardial infarction (CAMI) registry[J]. BMC Cardiovasc Disord, 2017, 17(1):2.
|
| [8] |
Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk[J]. Eur Heart J, 2019, 40(31):2632-2653.
|
| [9] |
Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study[J]. Thromb Haemost, 2012, 107(6):1172-1179.
|
| [10] |
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5):373-498.
|
| [11] |
张澍, 杨艳敏, 黄从新, 等. 中国心房颤动患者卒中预防规范(2017)[J]. 中华心律失常学杂志, 2018, 22(1):17-30.
|
| [12] |
Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2022, 79(2):e21-e129.
|
| [13] |
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2021, 42(14):1289-1367.
|
| [14] |
Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial[J]. Lancet, 2006, 367(9526):1903-1912.
|
| [15] |
van Rein N, Heide-Jørgensen U, Lijfering WM, et al. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy[J]. Circulation, 2019, 139(6):775-786.
|
| [16] |
Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial[J]. Lancet, 2013, 381(9872):1107-1115.
|
| [17] |
Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial[J]. J Am Coll Cardiol, 2015, 65(16):1619-1629.
|
| [18] |
Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI[J]. N Engl J Med, 2016, 375(25):2423-2434.
|
| [19] |
Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation[J]. N Engl J Med, 2017, 377(16):1513-1524.
|
| [20] |
Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or pci in atrial fibrillation[J]. N Engl J Med, 2019, 380(16):1509-1524.
|
| [21] |
Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial[J]. Lancet, 2019, 394(10206):1335-1343.
|
| [22] |
Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials[J]. Eur Heart J, 2019, 40(46):3757-3767.
|
| [23] |
Smits PC, Frigoli E, Tijssen J, et al. Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial[J]. Circulation, 2021, 144(15):1196-1211.
|
| [24] |
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology/american Heart association task force on clinical practice guidelines and the heart rhythm society[J]. J Am Coll Cardiol, 2019, 74(1):104-132.
|
| [25] |
Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European association for cardio-thoracic surgery (EACTS), authors/task force members, et al. guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the european Society of Cardiology (ESC)[J]. Eur Heart J, 2010, 31(19): 2369–2429.
|
| [26] |
Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective[J]. Thromb Haemost, 2011, 106(4):572-584.
|
| [27] |
Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a north american perspective: executive summary[J]. Circ Cardiovasc Interv, 2011, 4(5):522-534.
|
| [28] |
Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective-2016 Update.[J]. Circ Cardiovasc Interv, 2016, 9(11): e004395.
|
| [29] |
Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective-2018 update[J]. Circulation, 2018, 138(5):527-536.
|
| [30] |
Lip G, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)[J]. Europace, 2019, 21(2):192-193.
|
| [31] |
Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update[J]. Circulation, 2021, 143(6):583-596.
|
| [32] |
中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 冠心病合并心房颤动患者抗栓管理中国专家共识[J]. 中华心血管病杂志, 2020, 48(7):552-564.
|
| [33] |
Lopes RD, Leonardi S, Wojdyla DM, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial[J]. Circulation, 2020, 141(9):781-783.
|
| [34] |
Alexander JH, Wojdyla D, Vora AN, et al. Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS[J]. Circulation, 2020, 141(20):1618-1627.
|
| [35] |
Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period[J]. Eur Heart J, 2009, 30(22):2714-2721.
|